Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMB-15 in Locally Advanced or Metastatic Solid Tumors
NCT07607054Phase 1Recruiting
- Sponsor
- EpimAb Biotherapeutics
- Start
- May 2026
- Primary completion
- May 2029
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of EMB-15 in solid tumor, sponsored by EpimAb Biotherapeutics. Primary endpoints: Incidence and severity of adverse events, Incidence of serious adverse events and 3 more. Started May 2026; status: recruiting.
02
Drugs
EMB-15
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07607054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07607054.